Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 56,503 |
|
|||||
| News | - | ||||||
| Day High | 1.45 | Low High |
|||||
| Day Low | 1.29 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| NextCure Inc | NXTC | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.06 | 4.65% | 1.35 | 23:00:08 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.30 | 1.29 | 1.45 | 1.35 | 1.29 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 612 | 56,503 | US$ 1.36 | US$ 77,061 | - | 0.98 - 2.57 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 15:00:00 | 1,214 | US$ 1.35 | USD |
NextCure Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 38.23M | 27.90M | - | 0 | -62.72M | -2.25 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
NextCure News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NXTC Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.58 | 1.72 | 1.27 | 1.46 | 117,234 | -0.23 | -14.56% |
| 1 Month | 2.23 | 2.57 | 1.27 | 2.01 | 165,086 | -0.88 | -39.46% |
| 3 Months | 1.31 | 2.57 | 1.23 | 1.76 | 312,407 | 0.04 | 3.05% |
| 6 Months | 1.06 | 2.57 | 1.00 | 1.62 | 192,232 | 0.29 | 27.36% |
| 1 Year | 1.52 | 2.57 | 0.98 | 1.60 | 121,706 | -0.17 | -11.18% |
| 3 Years | 9.62 | 10.23 | 0.98 | 4.49 | 162,157 | -8.27 | -85.97% |
| 5 Years | 15.55 | 109.00 | 0.98 | 16.86 | 238,355 | -14.20 | -91.32% |
NextCure Description
| NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. It is focused on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. The company's product candidate, NC318, is an immunomedicine against an immunomodulatory receptor called Siglec-15, or S15. |
